Editorial orientation provided by MedAPI — not part of the coding instruction.
C33 describes a primary malignant neoplasm arising in the trachea. Primary tracheal cancers are rare and may present late because progressive airway narrowing can initially resemble asthma or chronic obstructive airway disease.
Common Histologies
- Squamous cell carcinoma — the most common adult histology; strongly associated with tobacco exposure
- Adenoid cystic carcinoma — a salivary gland–type tumor characterized by submucosal and perineural spread
- Mucoepidermoid carcinoma and other salivary gland–type carcinomas
- Less commonly, neuroendocrine carcinoma, sarcoma, or other rare malignant tumors
Common Symptoms
- Persistent cough (R05.3), dyspnea (R06.00), wheezing (R06.2), or reduced exercise tolerance (R53.83)
- Stridor or other signs of central airway obstruction (R06.1)
- Hemoptysis (R04.2)
- Recurrent or nonresolving pneumonia (J18.9)
- Hoarseness or dysphagia when adjacent structures are involved (R49.0)
Diagnosis
Evaluation commonly includes contrast-enhanced CT of the neck and chest to define tumor length, airway narrowing, extratracheal extension, nodal disease, and surgical anatomy. Bronchoscopy permits direct assessment and biopsy but may require airway precautions in patients with critical obstruction. PET/CT or other imaging may be used to evaluate nodal and distant disease.
Staging
A universally applied, dedicated staging system for primary tracheal carcinoma is not consistently used. Clinical assessment should document:
- Tumor location and longitudinal extent
- Degree of airway obstruction
- Invasion of the larynx, esophagus, thyroid, major vessels, mediastinum, or recurrent laryngeal nerves
- Regional lymph-node involvement
- Distant metastases
- Resectability and the feasibility of airway reconstruction
Molecular Markers
Testing is guided by histology and disease setting. Examples include MYB or MYBL1 rearrangements in adenoid cystic carcinoma and CRTC1/3–MAML2 fusions in mucoepidermoid carcinoma. PD-L1 assessment and broader genomic profiling may be considered for advanced disease when results could guide systemic therapy.
Common Treatments
- Segmental tracheal resection with primary reconstruction for localized, technically resectable disease
- Postoperative radiation for selected high-risk features, positive or close margins, or histologies prone to infiltrative spread
- Definitive radiation, sometimes with systemic therapy, for unresectable disease
- Histology-directed systemic therapy for recurrent, metastatic, or locally advanced disease
- Bronchoscopic debulking, laser or thermal ablation, dilation, or airway stenting for urgent or palliative relief of obstruction
Management generally requires a multidisciplinary team experienced in thoracic surgery, interventional pulmonology, radiation oncology, and head-and-neck or thoracic oncology.
Scope Note
C33 identifies the anatomic site of a primary malignant neoplasm of the trachea. It does not encode histologic subtype, molecular findings, grade, stage, nodal status, metastatic status, airway obstruction severity, or treatment intent. Malignancy originating in another organ with direct extension to or metastasis involving the trachea should not be represented as a primary C33 neoplasm solely because the trachea is involved. Tobacco use, dependence, history, or environmental exposure may be captured with additional codes when documented.